TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism
<p>Abstract</p> <p>Background</p> <p>Muscle atrophy associated with various pathophysiological conditions represents a major health problem, because of its contribution to the deterioration of patient status and its effect on mortality. Although the involvement of pro-i...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-01-01
|
| Series: | Skeletal Muscle |
| Online Access: | http://www.skeletalmusclejournal.com/content/2/1/2 |
| _version_ | 1819117394086330368 |
|---|---|
| author | De Larichaudy Joffrey Zufferli Alessandra Serra Filippo Isidori Andrea M Naro Fabio Dessalle Kevin Desgeorges Marine Piraud Monique Cheillan David Vidal Hubert Lefai Etienne Némoz Georges |
| author_facet | De Larichaudy Joffrey Zufferli Alessandra Serra Filippo Isidori Andrea M Naro Fabio Dessalle Kevin Desgeorges Marine Piraud Monique Cheillan David Vidal Hubert Lefai Etienne Némoz Georges |
| author_sort | De Larichaudy Joffrey |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Muscle atrophy associated with various pathophysiological conditions represents a major health problem, because of its contribution to the deterioration of patient status and its effect on mortality. Although the involvement of pro-inflammatory cytokines in this process is well recognized, the role of sphingolipid metabolism alterations induced by the cytokines has received little attention.</p> <p>Results</p> <p>We addressed this question both <it>in vitro </it>using differentiated myotubes treated with TNF-α, and <it>in vivo </it>in a murine model of tumor-induced cachexia. Myotube atrophy induced by TNF-α was accompanied by a substantial increase in cell ceramide levels, and could be mimicked by the addition of exogenous ceramides. It could be prevented by the addition of ceramide-synthesis inhibitors that targeted either the <it>de novo </it>pathway (myriocin), or the sphingomyelinases (GW4869 and 3-<it>O</it>-methylsphingomyelin). In the presence of TNF-α, ceramide-synthesis inhibitors significantly increased protein synthesis and decreased proteolysis. In parallel, they lowered the expression of both the <it>Atrogin-1 </it>and <it>LC3b </it>genes, involved in muscle protein degradation by proteasome and in autophagic proteolysis, respectively, and increased the proportion of inactive, phosphorylated Foxo3 transcription factor. Furthermore, these inhibitors increased the expression and/or phosphorylation levels of key factors regulating protein metabolism, including phospholipase D, an activator of mammalian target of rapamycin (mTOR), and the mTOR substrates S6K1 and Akt. <it>In vivo</it>, C26 carcinoma implantation induced a substantial increase in muscle ceramide, together with drastic muscle atrophy. Treatment of the animals with myriocin reduced the expression of the atrogenes <it>Foxo3 </it>and <it>Atrogin-1</it>, and partially protected muscle tissue from atrophy.</p> <p>Conclusions</p> <p>Ceramide accumulation induced by TNF-α or tumor development participates in the mechanism of muscle-cell atrophy, and sphingolipid metabolism is a logical target for pharmacological or nutritional interventions aiming at preserving muscle mass in pathological situations.</p> |
| first_indexed | 2024-12-22T05:32:17Z |
| format | Article |
| id | doaj.art-ff3f4b4153e845adbac378da53178d9e |
| institution | Directory Open Access Journal |
| issn | 2044-5040 |
| language | English |
| last_indexed | 2024-12-22T05:32:17Z |
| publishDate | 2012-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Skeletal Muscle |
| spelling | doaj.art-ff3f4b4153e845adbac378da53178d9e2022-12-21T18:37:25ZengBMCSkeletal Muscle2044-50402012-01-0121210.1186/2044-5040-2-2TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolismDe Larichaudy JoffreyZufferli AlessandraSerra FilippoIsidori Andrea MNaro FabioDessalle KevinDesgeorges MarinePiraud MoniqueCheillan DavidVidal HubertLefai EtienneNémoz Georges<p>Abstract</p> <p>Background</p> <p>Muscle atrophy associated with various pathophysiological conditions represents a major health problem, because of its contribution to the deterioration of patient status and its effect on mortality. Although the involvement of pro-inflammatory cytokines in this process is well recognized, the role of sphingolipid metabolism alterations induced by the cytokines has received little attention.</p> <p>Results</p> <p>We addressed this question both <it>in vitro </it>using differentiated myotubes treated with TNF-α, and <it>in vivo </it>in a murine model of tumor-induced cachexia. Myotube atrophy induced by TNF-α was accompanied by a substantial increase in cell ceramide levels, and could be mimicked by the addition of exogenous ceramides. It could be prevented by the addition of ceramide-synthesis inhibitors that targeted either the <it>de novo </it>pathway (myriocin), or the sphingomyelinases (GW4869 and 3-<it>O</it>-methylsphingomyelin). In the presence of TNF-α, ceramide-synthesis inhibitors significantly increased protein synthesis and decreased proteolysis. In parallel, they lowered the expression of both the <it>Atrogin-1 </it>and <it>LC3b </it>genes, involved in muscle protein degradation by proteasome and in autophagic proteolysis, respectively, and increased the proportion of inactive, phosphorylated Foxo3 transcription factor. Furthermore, these inhibitors increased the expression and/or phosphorylation levels of key factors regulating protein metabolism, including phospholipase D, an activator of mammalian target of rapamycin (mTOR), and the mTOR substrates S6K1 and Akt. <it>In vivo</it>, C26 carcinoma implantation induced a substantial increase in muscle ceramide, together with drastic muscle atrophy. Treatment of the animals with myriocin reduced the expression of the atrogenes <it>Foxo3 </it>and <it>Atrogin-1</it>, and partially protected muscle tissue from atrophy.</p> <p>Conclusions</p> <p>Ceramide accumulation induced by TNF-α or tumor development participates in the mechanism of muscle-cell atrophy, and sphingolipid metabolism is a logical target for pharmacological or nutritional interventions aiming at preserving muscle mass in pathological situations.</p>http://www.skeletalmusclejournal.com/content/2/1/2 |
| spellingShingle | De Larichaudy Joffrey Zufferli Alessandra Serra Filippo Isidori Andrea M Naro Fabio Dessalle Kevin Desgeorges Marine Piraud Monique Cheillan David Vidal Hubert Lefai Etienne Némoz Georges TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism Skeletal Muscle |
| title | TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism |
| title_full | TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism |
| title_fullStr | TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism |
| title_full_unstemmed | TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism |
| title_short | TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism |
| title_sort | tnf α and tumor induced skeletal muscle atrophy involves sphingolipid metabolism |
| url | http://www.skeletalmusclejournal.com/content/2/1/2 |
| work_keys_str_mv | AT delarichaudyjoffrey tnfaandtumorinducedskeletalmuscleatrophyinvolvessphingolipidmetabolism AT zufferlialessandra tnfaandtumorinducedskeletalmuscleatrophyinvolvessphingolipidmetabolism AT serrafilippo tnfaandtumorinducedskeletalmuscleatrophyinvolvessphingolipidmetabolism AT isidoriandream tnfaandtumorinducedskeletalmuscleatrophyinvolvessphingolipidmetabolism AT narofabio tnfaandtumorinducedskeletalmuscleatrophyinvolvessphingolipidmetabolism AT dessallekevin tnfaandtumorinducedskeletalmuscleatrophyinvolvessphingolipidmetabolism AT desgeorgesmarine tnfaandtumorinducedskeletalmuscleatrophyinvolvessphingolipidmetabolism AT piraudmonique tnfaandtumorinducedskeletalmuscleatrophyinvolvessphingolipidmetabolism AT cheillandavid tnfaandtumorinducedskeletalmuscleatrophyinvolvessphingolipidmetabolism AT vidalhubert tnfaandtumorinducedskeletalmuscleatrophyinvolvessphingolipidmetabolism AT lefaietienne tnfaandtumorinducedskeletalmuscleatrophyinvolvessphingolipidmetabolism AT nemozgeorges tnfaandtumorinducedskeletalmuscleatrophyinvolvessphingolipidmetabolism |